Table 2. Clinical and demographic characteristics of patients with human circovirus infection, Hong Kong*.
| Patient no. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|---|---|---|---|---|---|---|---|---|
| Age |
15 |
59 |
39 |
53 |
67 |
75 |
40 |
42 |
| Sex |
M |
M |
F |
F |
M |
M |
M |
F |
| Immunosuppressive condition |
Neuroblastoma |
None |
None |
Kidney graft† |
Liver graft† |
None |
None |
Liver graft† |
| Organs / blood products |
Y |
N |
N |
Y |
Y |
N |
N |
Y |
| Peak ALT, U/L |
672 |
413 |
109 |
96 |
532 |
469 |
401 |
983 |
| Peak ALP, U/L |
2288 |
139 |
174 |
928 |
601 |
274 |
484 |
168 |
| R factor |
0.6 |
4.7 |
1.6 |
0.3 |
1.4 |
3.2 |
1.6 |
15.2 |
| Peak bilirubin, µmol/L |
91 |
9 |
23 |
44 |
301 |
28 |
281 |
52 |
| Duration of hepatitis |
Chronic |
Acute |
Acute |
Acute |
Acute, relapse |
Acute |
Acute |
Acute |
| Outcome |
Death |
Survived |
Death |
Survived |
Death |
Survived |
Survived |
Survived |
| Clinician diagnosis |
NIC |
NIC |
NIC |
NIC |
Chronic rejection |
COVID-19 |
Cholangitis |
Anastomotic stricture |
| Expert 1 diagnosis |
Drug-induced hepatitis |
NIC |
Ischemic hepatitis |
Drug-induced cholestasis |
NIC |
COVID-19 |
Cholangitis |
Rejection |
| Expert 2 diagnosis | NIC | NIC | NIC | NIC | NIC | Gallstone | Cholangitis | Anastomotic stricture |
*ALP, alkaline phosphatase; ALT, alanine aminotransferase; NIC, no identifiable single cause for hepatitis. †Time from transplantation to hepatitis: patient 4, 1 month; patient 5, 15 years; patient 8, 22 months.